115 related articles for article (PubMed ID: 6735434)
21. The study of antibodies and antigens dissociated from the immune complexes extracted from ovarian carcinoma ascitic fluid.
Qian HN; Feng J; Fu TY
Gynecol Oncol; 1985 Jan; 20(1):100-8. PubMed ID: 3965372
[TBL] [Abstract][Full Text] [Related]
22. Immune response to a mammary adenocarcinoma. V. Sera from tumor-bearing rats contain multiple factors blocking cell-mediated cytotoxicity.
Huber SA; Lucas ZJ
J Immunol; 1978 Dec; 121(6):2485-9. PubMed ID: 722081
[TBL] [Abstract][Full Text] [Related]
23. Identification and purification of an organ specific, tumor membrane associated antigen from a spontaneously metastasizing rat mammary carcinoma.
Ghosh SK; Grossberg AL; Kim U; Pressman D
Immunochemistry; 1978 Jun; 15(6):345-52. PubMed ID: 100414
[No Abstract] [Full Text] [Related]
24. Growth of rat mammary adenocarcinoma cells in semisolid clonogenic medium not correlated with spontaneous metastatic behavior: heterogeneity in the metastatic, antigenic, enzymatic, and drug sensitivity properties of cells from different sized colonies.
Nicolson GL; Lembo TM; Welch DR
Cancer Res; 1988 Jan; 48(2):399-404. PubMed ID: 2825974
[TBL] [Abstract][Full Text] [Related]
25. Comparison of iodinated antigens of metastatic and non-metastatic mammary adenocarcinoma cells.
Abbas MK; Yoo TJ
Int Arch Allergy Appl Immunol; 1983; 72(3):193-8. PubMed ID: 6618681
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of the incidence of metastasis in tumor-resected mice. Influence of soluble tumor extract and splenectomy.
Klein S; de Bonaparte YP; de D'Elia I
Invasion Metastasis; 1985; 5(5):309-16. PubMed ID: 4030247
[TBL] [Abstract][Full Text] [Related]
27. Tumor therapy of neoplastic diseases with tumor cells and neuraminidase: experimental studies on chessboard vaccination in transplantation tumors.
Sedlacek HH; Bengelsdorff KH; Hagmayer G; Seiler FR
Int J Immunopharmacol; 1987; 9(7):841-50. PubMed ID: 3429076
[TBL] [Abstract][Full Text] [Related]
28. Differential permeability of lymphatic and blood vessels in determining the route of metastasis as demonstrated by indirect lymphography.
Kim U; Park HC; Choi KH
Clin Exp Metastasis; 1988; 6(4):291-9. PubMed ID: 3359712
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of in vitro lymphoproliferative responses by in vivo passaged rat 13762 mammary adenocarcinoma cells. II. Evidenceth Kilham rat virus is responsible for the inhibitory effect.
Campbell DA; Staal SP; Manders EK; Bonnard GD; Oldham RK; Salzman LA; Herberman RB
Cell Immunol; 1977 Oct; 33(2):378-91. PubMed ID: 912764
[No Abstract] [Full Text] [Related]
30. Suitability of rat mammary adenocarcinoma 13762 as a model for BCG immunotherapy.
Kreider JW; Bartlett GL; Purnell DM
J Natl Cancer Inst; 1976 Apr; 56(4):797-802. PubMed ID: 815563
[TBL] [Abstract][Full Text] [Related]
31. IgA containing immune complexes in dogs bearing a spontaneous mammary adenocarcinoma.
Balint J; Nagai T; Ikeda Y; Meek K; Terman DS
Clin Exp Immunol; 1982 Aug; 49(2):433-40. PubMed ID: 6982137
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibody against a cryptic carbohydrate antigen of murine and human lymphocytes. I. Antigen expression in non-cryptic or unsubstituted form on certain murine lymphomas, on a spontaneous murine mammary carcinoma, and on several human adenocarcinomas.
Longenecker BM; Rahman AF; Leigh JB; Purser RA; Greenberg AH; Willans DJ; Keller O; Petrik PK; Thay TY; Suresh MR
Int J Cancer; 1984 Jan; 33(1):123-9. PubMed ID: 6198295
[TBL] [Abstract][Full Text] [Related]
33. Influence of immunotherapeutic agents on the progression of spontaneously arising, metastasizing rat mammary adenocarcinomas of varying immunogenicities.
Greager JA; Baldwin RW
Cancer Res; 1978 Jan; 38(1):69-73. PubMed ID: 618584
[No Abstract] [Full Text] [Related]
34. Tube leukocyte adherence-inhibition response to related and unrelated tumor antigens in mammary tumor-bearing mice.
Chattopadhyay U; Guha S
Tumori; 1983 Aug; 69(4):299-303. PubMed ID: 6623652
[TBL] [Abstract][Full Text] [Related]
35. In vivo release of glycoprotein I from the Ha subline of TA3 murine tumor into ascites fluid and serum.
Cooper AG; Codington JF; Brown MC
Proc Natl Acad Sci U S A; 1974 Apr; 71(4):1224-8. PubMed ID: 4524634
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B.
Sleeman JP; Kim U; LePendu J; Howells N; Coquerelle T; Ponta H; Herrlich P
Oncogene; 1999 Aug; 18(31):4485-94. PubMed ID: 10442639
[TBL] [Abstract][Full Text] [Related]
37. Systemic adoptive transfer of immunity to 13762A rat mammary adenocarcinoma.
Boyer CM; Kreider JW; Bartlett GL
Cancer Res; 1981 Jun; 41(6):2394-400. PubMed ID: 6972251
[TBL] [Abstract][Full Text] [Related]
38. The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens.
Lu H; Knutson KL; Gad E; Disis ML
Cancer Res; 2006 Oct; 66(19):9754-61. PubMed ID: 17018635
[TBL] [Abstract][Full Text] [Related]
39. Localization of I 125 labelled antibodies against tumour-associated proteins from experimental rat mammary neoplasms.
Kellen JA; Lo JS
Res Commun Chem Pathol Pharmacol; 1973 Mar; 5(2):411-20. PubMed ID: 4121632
[No Abstract] [Full Text] [Related]
40. Lack of production of myoepithelial variants by cloned epithelial cell lines derived from the TMT-081 metastasizing rat mammary tumor.
Dunnington DJ; Kim U; Hughes CM; Monaghan P; Rudland PS
Cancer Res; 1984 Nov; 44(11):5338-46. PubMed ID: 6488188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
